Ossianix, an early stage biopharmaceutical startup that utilizes shark antibodies as a model for drugs to treat central nervous system disorders, has received a strategic investment from Danish pharmaceutical company H Lundbeck.The investment amount was not disclosed, but Dr. Frank Walsh, cofounder and CEO of Ossianix, said it would be enough to fund the company [...]